Publications and Promotional Materials Sample Clauses

Publications and Promotional Materials. A copy of all printed programs, catalogues, press releases, invitations, newsletters, annual reports, postcard announcements, brochures, or other material that is published in conjunction with the services outlined in Section I shall be sent to FCAC Division Manager, FCAC Program Development Specialist, and to the members of Arts Council immediately upon publication and at least three (3) weeks prior to the County-funded performances/presentations. Correspondence to FCAC Division Manager and FCAC Program Development Specialist shall be mailed to them at the Division of Arts & Culture’s main office: 000 Xxxxx Xx., SW, Suite 2030, Atlanta, GA 30303. Correspondence to Arts Council members shall be directed to their individual addresses using the mailing list provided to Contractor at the beginning of the contract cycle or any updates distributed by FCAC during the contract period.
Sample 1
AutoNDA by SimpleDocs
Publications and Promotional Materials. Licensee shall submit to Takeda for its review any proposed academic, scientific or medical peer reviewed publication by Licensee, its Affiliates and its or their sublicensees that relates to the Compound or a Product. Licensee shall also submit to Takeda for its review any proposed academic, scientific or medical publication or public *** Certain Confidential Information Omitted presentation that contains Takeda Know-How or Joint Know-How that has not been previously publicly disclosed or otherwise approved by Takeda to be publicly disclosed, for the purposes of determining whether any portion of the proposed publication or presentation should be modified or deleted so as to preserve the value of such Takeda Know-How and Joint Know-How. Licensee shall consider all comments provided by Takeda in good faith, including comments regarding the potential adverse impact on Exploitation of Compound and/or Product outside of the Territory. Takeda shall submit to Licensee for its review any proposed academic, scientific or medical publication or public presentation that contains Joint Know-How that has not been previously publicly disclosed or otherwise approved by Licensee to be publicly disclosed, for the purposes of determining whether any portion of the proposed publication or presentation should be modified or deleted so as to preserve the value of such Joint Know-How. Takeda shall consider all comments provided by Licensee in good faith, including comments regarding the potential adverse impact on Exploitation of Compound and/or Product in the Territory. Written copies of any proposed publication or presentation required to be submitted hereunder shall be submitted to the applicable Party no later than [***] before submission for publication or presentation (the “Review Period”). The Party receiving such submission shall provide its comments with respect to such publications and presentations within [***] of its receipt of such written copy. The Review Period may be extended for an additional [***] in the event such receiving Party can, within [***] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Each Party shall comply, and shall cause its Affiliates and sublicensees to comply, with (i) standard academic practice regarding authorship of scientific publications and recognition of contribution of the other Party in any publication governed by this Section 11.7, incl...
Sample 1Sample 2
Publications and Promotional Materials. (a) As between the Parties, (i) Licensee, its Affiliates and its or their (Sub)licensees will have the sole right to publish academic, scientific or medical peer reviewed publications that relate to the Compound or a Product, other than any publication of data resulting from Clinical Trials conducted by Takeda, its Affiliates and its or their (Sub)licensees with respect to Development of Product for Regulatory Approval in Japan, and (ii) Takeda, its Affiliates and its or their (Sub)licensees will have the sole right to publish data resulting from Clinical Trials conducted by Takeda, its Affiliates and its or their (Sub)licensees with respect to Development of Product for Regulatory Approval in Japan.
Sample 1Sample 2

Related to Publications and Promotional Materials

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

  • Regulatory Filings NYISO and Connecting Transmission Owner shall file this Agreement (and any amendment hereto) with the appropriate Governmental Authority, if required. Any information related to studies for interconnection asserted by Developer to contain Confidential Information shall be treated in accordance with Article 22 of this Agreement and Attachment F to the ISO OATT. If the Developer has executed this Agreement, or any amendment thereto, the Developer shall reasonably cooperate with NYISO and Connecting Transmission Owner with respect to such filing and to provide any information reasonably requested by NYISO and Connecting Transmission Owner needed to comply with Applicable Laws and Regulations.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

Time is Money Join Law Insider Premium to draft better contracts faster.